~~<i id='014664E8B7'><strike id='014664E8B7'><tt id='014664E8B7'><pre id='014664E8B7'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-09-29 04:28:02 Page View：1144

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Treeline, Josh Bilenker's next biotech, is cloaked in mystery
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

focus

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Scientists inch closer to single

AdobeWhatisthebestwaytofixfaultybloodcells,anddosoforthemostpeople?That’sthequestionahordeofgeneedit

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

APPhoto/TedS.WarrenJoshBilenker’slastcompany,LoxoOncology,waspurchasedbyEliLillyfor$8billion.Nosurpr